Search Results

You are looking at 21 - 30 of 463 items for

  • Abstract: adrenarche x
  • Abstract: amenorrhoea x
  • Abstract: fertility x
  • Abstract: Gender x
  • Abstract: Hypogonadism x
  • Abstract: infertility x
  • Abstract: menarche x
  • Abstract: menopause x
  • Abstract: testes x
  • Abstract: Turner x
  • Abstract: sperm* x
  • Abstract: ovary x
  • Abstract: follicles x
Clear All Modify Search
Eleftherios E Deiktakis Laboratory of Clinical Chemistry, School of Medicine, University of Crete, Heraklion, Greece

Search for other papers by Eleftherios E Deiktakis in
Google Scholar
PubMed
Close
,
Eleftheria Ieronymaki Laboratory of Clinical Chemistry, School of Medicine, University of Crete, Heraklion, Greece

Search for other papers by Eleftheria Ieronymaki in
Google Scholar
PubMed
Close
,
Peter Zarén Department of Translational Medicine, Lund University, Malmö, Sweden

Search for other papers by Peter Zarén in
Google Scholar
PubMed
Close
,
Agnes Hagsund Department of Translational Medicine, Lund University, Malmö, Sweden

Search for other papers by Agnes Hagsund in
Google Scholar
PubMed
Close
,
Elin Wirestrand Department of Translational Medicine, Lund University, Malmö, Sweden

Search for other papers by Elin Wirestrand in
Google Scholar
PubMed
Close
,
Johan Malm Department of Translational Medicine, Lund University, Malmö, Sweden

Search for other papers by Johan Malm in
Google Scholar
PubMed
Close
,
Christos Tsatsanis Laboratory of Clinical Chemistry, School of Medicine, University of Crete, Heraklion, Greece

Search for other papers by Christos Tsatsanis in
Google Scholar
PubMed
Close
,
Ilpo T Huhtaniemi Department of Translational Medicine, Lund University, Malmö, Sweden
Imperial College London, Institute of Reproductive and Developmental Biology, London, UK

Search for other papers by Ilpo T Huhtaniemi in
Google Scholar
PubMed
Close
,
Aleksander Giwercman Department of Translational Medicine, Lund University, Malmö, Sweden
Malmö University Hospital, Reproductive Medicine Center, Malmö, Sweden

Search for other papers by Aleksander Giwercman in
Google Scholar
PubMed
Close
, and
Yvonne Lundberg Giwercman Department of Translational Medicine, Lund University, Malmö, Sweden

Search for other papers by Yvonne Lundberg Giwercman in
Google Scholar
PubMed
Close

Objective

During androgen ablation in prostate cancer by the standard gonadotropin-releasing hormone (GnRH) agonist treatment, only luteinizing hormone (LH) is permanently suppressed while circulating follicle-stimulating hormone (FSH) rebounds. We explored direct prostatic effects of add-back FSH, after androgen ablation with GnRH antagonist, permanently suppressing both gonadotropins.

Methods

The effects of recombinant human (rFSH) were examined in mice treated with vehicle (controls), GnRH antagonist degarelix (dgx), dgx + rFSH, dgx + flutamide, or dgx + rFSH + flutamide for 4 weeks. Prostates and testes size and expression of prostate-specific and/or androgen-responsive genes were measured. Additionally, 33 young men underwent dgx-treatment. Seventeen were supplemented with rFSH (weeks 1–5), and all with testosterone (weeks 4–5). Testosterone, gondotropins, prostate-specific antigen (PSA), and inhibin B were measured.

Results

In dgx and dgx + flutamide treated mice, prostate weight/body weight was 91% lower than in controls, but 41 and 11%, respectively, was regained by rFSH treatment (P = 0.02). The levels of seminal vesicle secretion 6, Pbsn, Nkx3.1, beta-microseminoprotein, and inhibin b were elevated in dgx + rFSH-treated animals compared with only dgx treated (all P < 0.05). In men, serum inhibin B rose after dgx treatment but was subsequently suppressed by testosterone. rFSH add-back had no effect on PSA levels.

Conclusions

These data provide novel evidence for the direct effects of FSH on prostate size and gene expression in chemically castrated mice. However, in chemically castrated men, FSH had no effect on PSA production. Whether FSH effects on the prostate in humans also require suppression of the residual adrenal-derived androgens and/or a longer period of rFSH stimulation, remains to be explored.

Open access
Jennifer K Y Ko Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China

Search for other papers by Jennifer K Y Ko in
Google Scholar
PubMed
Close
,
Jinghua Shi Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China

Search for other papers by Jinghua Shi in
Google Scholar
PubMed
Close
,
Raymond H W Li Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China

Search for other papers by Raymond H W Li in
Google Scholar
PubMed
Close
,
William S B Yeung Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China

Search for other papers by William S B Yeung in
Google Scholar
PubMed
Close
, and
Ernest H Y Ng Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China

Search for other papers by Ernest H Y Ng in
Google Scholar
PubMed
Close

Objective

Vitamin D receptors are present in the female reproductive tract. Studies on the association between serum vitamin D level and pregnancy rate of in vitro fertilization (IVF) showed inconsistent results and focused on a single fresh or frozen embryo transfer cycle. The objective of our study was to evaluate if serum vitamin D level before ovarian stimulation was associated with the cumulative live birth rate (CLBR) of the first IVF cycle.

Design

Retrospective cohort study.

Methods

Women who underwent the first IVF cycle from 2012 to 2016 at a university-affiliated reproductive medicine center were included. Archived serum samples taken before ovarian stimulation were analyzed for 25(OH)D levels using liquid chromatography-mass spectrometry.

Results

In total, 1113 had pregnancy outcome from the completed IVF cycle. The median age (25th–75th percentile) of the women was 36 (34–38) years and serum 25(OH)D level was 53.4 (41.9–66.6) nmol/L. The prevalence of vitamin D deficiency (less than 50 nmol/L) was 42.2%. The CLBR in the vitamin D-deficient group was significantly lower compared to the non-deficient group (43.9%, 208/474 vs 50.9%, 325/639, P  = 0.021, unadjusted), and after controlling for women’s age, BMI, antral follicle count, type and duration of infertility. There were no differences in the clinical/ongoing pregnancy rate, live birth rate and miscarriage rate in the fresh cycle between the vitamin D deficient and non-deficient groups.

Conclusions

Vitamin D deficiency was prevalent in infertile women in subtropical Hong Kong. The CLBR of the first IVF cycle in the vitamin D-deficient group was significantly lower compared to the non-deficient group.

Open access
M Jensterle Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia

Search for other papers by M Jensterle in
Google Scholar
PubMed
Close
,
A Podbregar University Rehabilitation Institute Republic of Slovenia, Ljubljana, Slovenia

Search for other papers by A Podbregar in
Google Scholar
PubMed
Close
,
K Goricar University of Ljubljana, Faculty of Medicine, Institute of Biochemistry, Pharmacogenetics Laboratory, Ljubljana, Slovenia

Search for other papers by K Goricar in
Google Scholar
PubMed
Close
,
N Gregoric Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia

Search for other papers by N Gregoric in
Google Scholar
PubMed
Close
, and
A Janez Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia

Search for other papers by A Janez in
Google Scholar
PubMed
Close

Lifestyle measures (LSMs) should be the first-line approach offered for obesity-related functional hypogonadism (FH). When LSMs fail, the role of testosterone replacement treatment (TRT) is unclear. GLP1 receptor agonist liraglutide is linked to progressive and sustained weight loss. A potential direct impact of GLP1 on hypothalamus-pituitary-testicular (HPT) axis was reported in animal models. We aimed to compare the effects of liraglutide and TRT on FH in obese men that had been poor responders to LSM, by means of reversal of FH and weight reduction. We designed a 16-week prospective randomized open-label study with 30 men (aged 46.5 ± 10.9 years, BMI 41.2 ± 8.4 kg/m2, mean ± s.d.) that were randomized to liraglutide 3.0 mg QD (LIRA) or 50 mg of 1% transdermal gel QD (TRT). Sexual function and anthropometric measures were assessed. Fasting blood was drawn for determination of endocrine and metabolic parameters followed by OGTT. Model-derived parameters including HOMAIR and calculated free testosterone (cFT) were calculated. Total testosterone significantly increased in both arms (+5.9 ± 7.2 in TRT vs +2.6 ± 3.5 nmol/L in LIRA) and led to improved sexual function. LIRA resulted in a significant increase of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (P < 0.001 for between-treatment effect). Subjects treated with LIRA lost on average 7.9 ± 3.8  kg compared with a 0.9 ± 4.5  kg loss in TRT (P < 0.001). Metabolic syndrome was resolved in two patients in LIRA and in no subjects in TRT. Liraglutide was superior to TRT in improving an overall health benefit in men with obesity-associated FH after LSM failed.

Open access
Giuseppe Grande Unit of Andrology and Reproductive Medicine, University Hospital of Padova, Padova, Italy

Search for other papers by Giuseppe Grande in
Google Scholar
PubMed
Close
,
Andrea Graziani Department of Medicine, University of Padova, Padova, Italy

Search for other papers by Andrea Graziani in
Google Scholar
PubMed
Close
,
Antonella Di Mambro Unit of Andrology and Reproductive Medicine, University Hospital of Padova, Padova, Italy

Search for other papers by Antonella Di Mambro in
Google Scholar
PubMed
Close
,
Riccardo Selice Unit of Andrology and Reproductive Medicine, University Hospital of Padova, Padova, Italy

Search for other papers by Riccardo Selice in
Google Scholar
PubMed
Close
, and
Alberto Ferlin Unit of Andrology and Reproductive Medicine, University Hospital of Padova, Padova, Italy
Department of Medicine, University of Padova, Padova, Italy

Search for other papers by Alberto Ferlin in
Google Scholar
PubMed
Close

Low bone mass is common in men with Klinefelter syndrome (KS), with a prevalence of 6–15% of osteoporosis and of 25–48% of osteopenia. Reduced bone mass has been described since adolescence and it might be related to both reduced bone formation and higher bone resorption. Although reduced testosterone levels are clearly involved in the pathogenesis, this relation is not always evident. Importantly, fracture risk is increased independently from bone mineral density (BMD) and testosterone levels. Here we discuss the pathogenesis of osteoporosis in patients with KS, with a particular focus on the role of testosterone and testis function. In fact, other hormonal mechanisms, such as global Leydig cell dysfunction, causing reduced insulin-like factor 3 and 25-OH vitamin D levels, and high follicle-stimulating hormone and estradiol levels, might be involved. Furthermore, genetic aspects related to the supernumerary X chromosome might be involved, as well as androgen receptor expression and function. Notably, body composition, skeletal mass and strength, and age at diagnosis are other important aspects. Although dual-energy x-ray absorptiometry is recommended in the clinical workflow for patients with KS to measure BMD, recent evidence suggests that alterations in the microarchitecture of the bones and vertebral fractures might be present even in subjects with normal BMD. Therefore, analysis of trabecular bone score, high-resolution peripheral quantitative computed tomography and vertebral morphometry seem promising tools to better estimate the fracture risk of patients with KS. This review also summarizes the evidence on the best available treatments for osteoporosis in men with KS, with or without hypogonadism.

Open access
Lára Ósk Eggertsdóttir Claessen Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
Department of Emergency Medicine, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland

Search for other papers by Lára Ósk Eggertsdóttir Claessen in
Google Scholar
PubMed
Close
,
Hafrún Kristjánsdóttir Physical Activity, Physical Education, Sport, and Health (PAPESH) Research Centre, Sports Science Department, School of Social Sciences, Reykjavik University, Reykjavik, Iceland

Search for other papers by Hafrún Kristjánsdóttir in
Google Scholar
PubMed
Close
,
María Kristín Jónsdóttir Mental Health Services, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland
Department of Psychology, School of Social Sciences, Reykjavik University, Reykjavik, Iceland

Search for other papers by María Kristín Jónsdóttir in
Google Scholar
PubMed
Close
,
Sigrún Helga Lund deCODE Genetics, Inc/Amgen Inc., Reykjavik, Iceland
School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland

Search for other papers by Sigrún Helga Lund in
Google Scholar
PubMed
Close
,
Ingunn Unnsteinsdóttir Kristensen Department of Psychology, School of Social Sciences, Reykjavik University, Reykjavik, Iceland

Search for other papers by Ingunn Unnsteinsdóttir Kristensen in
Google Scholar
PubMed
Close
, and
Helga Ágústa Sigurjónsdóttir Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
Department of Medicine, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland

Search for other papers by Helga Ágústa Sigurjónsdóttir in
Google Scholar
PubMed
Close

Objective

Pituitary dysfunction following mild traumatic brain injury can have serious physical and psychological consequences, making correct diagnosis and treatment essential. To the best of our knowledge, this study is the first to study the prevalence of pituitary dysfunction following mild traumatic brain injury in an all-female population following detailed endocrinological work-up after screening for pituitary dysfunction in female athletes.

Design

This is a retrospective cohort study.

Methods

Hormone screening blood tests, including serum blood values for thyroid-stimulating hormone, free thyroxin, insulin-like growth factor 1, prolactin, cortisol, follicle-stimulating hormone, luteinizing hormone, estrogen and progesterone, were taken in 133 female athletes. Results were repeatedly outside the reference value in 88 women necessitating further endocrinological evaluation. Two of those were lost to follow-up, and further endocrinological evaluation was performed in 86 participants.

Results

Six women (4.6%, n = 131) were diagnosed with hypopituitarism, four (3.1%) with central hypothyroidism and two with growth hormone deficiency (1.5%). Ten women (7.6%) had hyperprolactinemia, and four (3.1%) of them had prolactinoma. Medical treatment was initiated in 13 (9.9%) women. Significant prognostic factors were not found.

Conclusions

As 12.2% of female athletes with a history of mild traumatic brain injury had pituitary dysfunction (hypopituitarism 4.6%, hyperprolactinemia 7.6%), we conclude that pituitary dysfunction is an important consideration in post-concussion care. Hyperprolactinemia in the absence of prolactinoma may represent pituitary or hypothalamic injury following mild traumatic brain injury.

Significance statement

Mild traumatic brain injury (mTBI) has become a growing public health concern as 50 million people worldwide sustain a traumatic brain injury annually, with mTBI being the most common (70–90%). As studies on mTBI have focused on mostly male populations this study aims to explore pituitary dysfunction (PD) in female athletes following mTBI. To the best of our knowledge, it is the first all-female study on PD following mTBI.

The study found that 12.2% of the participating women had PD after mTBI. Six (4.6%) had hypopituitarism and ten (7.6%) had hyperprolactinemia. These findings suggest that PD following mTBI is an important consideration that endocrinologists and other medical staff working with athletes need to be aware of.

Open access
Arpna Sharma Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany

Search for other papers by Arpna Sharma in
Google Scholar
PubMed
Close
,
Vijay Simha Baddela Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany

Search for other papers by Vijay Simha Baddela in
Google Scholar
PubMed
Close
,
Frank Becker Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany

Search for other papers by Frank Becker in
Google Scholar
PubMed
Close
,
Dirk Dannenberger Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany

Search for other papers by Dirk Dannenberger in
Google Scholar
PubMed
Close
,
Torsten Viergutz Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany

Search for other papers by Torsten Viergutz in
Google Scholar
PubMed
Close
, and
Jens Vanselow Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany

Search for other papers by Jens Vanselow in
Google Scholar
PubMed
Close

High-yielding dairy cows postpartum face the challenge of negative energy balance leading to elevated free fatty acids levels in the serum and follicular fluid thus affecting the ovarian function. Here, we investigated effects of physiological concentrations of palmitic acid (PA), stearic acid (SA) and oleic acid (OA) on the viability, steroid production and gene expression in a bovine granulosa cell (GC) culture model. Treatment with individual and combined fatty acids increased the CD36 gene expression, while no significant apoptotic effects were observed. Both PA and SA significantly upregulated the expression of FSHR, LHCGR, CYP19A1, HSD3B1, CCND2 and increased 17β-estradiol (E2) production, while OA downregulated the expression of these genes and reduced E2. Interestingly, STAR was equally downregulated by all fatty acids and combination treatment. E2 was significantly reduced after combination treatment. To validate the effects of OA, in vivo growing dominant follicles (10–19 mm) were injected with bovine serum albumin (BSA) with/without conjugated OA. The follicular fluid was recovered 48 h post injection. As in our in vitro model, OA significantly reduced intrafollicular E2 concentrations. In addition, expression of CD36 was significantly up- and that of CYP19A1 and STAR significantly downregulated in antral GC recovered from aspirated follicles. The ovulation rates of OA-injected follicles tended to be reduced. Our results indicate that elevated free fatty acid concentrations specifically target functional key genes in GC both in vitro and in vivo. Suggestively, this could be a possible mechanism through which elevated free fatty acids affect folliculogenesis in dairy cows postpartum.

Open access
Paraskevi Kazakou Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Paraskevi Kazakou in
Google Scholar
PubMed
Close
,
Stavroula A Paschou Endocrine Unit, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Stavroula A Paschou in
Google Scholar
PubMed
Close
,
Theodora Psaltopoulou Unit of Hematology and Oncology, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Theodora Psaltopoulou in
Google Scholar
PubMed
Close
,
Maria Gavriatopoulou Unit of Hematology and Oncology, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Maria Gavriatopoulou in
Google Scholar
PubMed
Close
,
Eleni Korompoki Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Eleni Korompoki in
Google Scholar
PubMed
Close
,
Katerina Stefanaki Endocrine Unit, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Katerina Stefanaki in
Google Scholar
PubMed
Close
,
Fotini Kanouta Department of Endocrinology, Alexandra Hospital, Athens, Greece

Search for other papers by Fotini Kanouta in
Google Scholar
PubMed
Close
,
Georgia N Kassi Department of Endocrinology, Alexandra Hospital, Athens, Greece

Search for other papers by Georgia N Kassi in
Google Scholar
PubMed
Close
,
Meletios-Athanasios Dimopoulos Unit of Hematology and Oncology, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Meletios-Athanasios Dimopoulos in
Google Scholar
PubMed
Close
, and
Asimina Mitrakou Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Asimina Mitrakou in
Google Scholar
PubMed
Close

Endocrine system plays a vital role in controlling human homeostasis. Understanding the possible effects of COVID-19 on endocrine glands is crucial to prevent and manage endocrine disorders before and during hospitalization in COVID-19-infected patients as well as to follow them up properly upon recovery. Many endocrine glands such as pancreas, hypothalamus and pituitary, thyroid, adrenal glands, testes, and ovaries have been found to express angiotensin-converting enzyme 2 receptors, the main binding site of the virus. Since the pandemic outbreak, various publications focus on the aggravation of preexisting endocrine diseases by COVID-19 infection or the adverse prognosis of the disease in endocrine patients. However, data on endocrine disorders both during the phase of the infection (early complications) and upon recovery (late complications) are scarce. The aim of this review is to identify and discuss early and late endocrine complications of COVID-19. The majority of the available data refer to glucose dysregulation and its reciprocal effect on COVID-19 infection with the main interest focusing on the presentation of new onset of diabetes mellitus. Thyroid dysfunction with low triiodothyronine, low thyroid stimulating hormone, or subacute thyroiditis has been reported. Adrenal dysregulation and impaired spermatogenesis in affected men have been also reported. Complications of other endocrine glands are still not clear. Considering the recent onset of COVID-19 infection, the available follow-up data are limited, and therefore, long-term studies are required to evaluate certain effects of COVID-19 on the endocrine glands.

Open access
Katica Bajuk Studen Nuclear Medicine Department, University Medical Centre Ljubljana, Ljubljana, Slovenia

Search for other papers by Katica Bajuk Studen in
Google Scholar
PubMed
Close
and
Marija Pfeifer Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Search for other papers by Marija Pfeifer in
Google Scholar
PubMed
Close

Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age. Besides hyperandrogenism, oligomenorrhea and fertility issues, it is associated with a high prevalence of metabolic disorders and cardiovascular risk factors. Several genetic polymorphisms have been identified for possible associations with cardiometabolic derangements in PCOS. Different PCOS phenotypes differ significantly in their cardiometabolic risk, which worsens with severity of androgen excess. Due to methodological difficulties, longer time-scale data about cardiovascular morbidity and mortality in PCOS and about possible beneficial effects of different treatment interventions is missing leaving many issues regarding cardiovascular risk unresolved.

Open access
Agnieszka Adamska Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Agnieszka Adamska in
Google Scholar
PubMed
Close
,
Paulina Tomczuk-Bobik Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Paulina Tomczuk-Bobik in
Google Scholar
PubMed
Close
,
Anna Beata Popławska-Kita Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Anna Beata Popławska-Kita in
Google Scholar
PubMed
Close
,
Katarzyna Siewko Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Katarzyna Siewko in
Google Scholar
PubMed
Close
,
Angelika Buczyńska Clinical Research Centre, Medical University of Bialystok, Białystok, Poland

Search for other papers by Angelika Buczyńska in
Google Scholar
PubMed
Close
,
Piotr Szumowski Department of Nuclear Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Piotr Szumowski in
Google Scholar
PubMed
Close
,
Łukasz Żukowski Department of Nuclear Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Łukasz Żukowski in
Google Scholar
PubMed
Close
,
Janusz Myśliwiec Department of Nuclear Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Janusz Myśliwiec in
Google Scholar
PubMed
Close
,
Monika Zbucka-Krętowska Department of Gynecological Endocrinology and Adolescent Gynecology, Medical University of Bialystok, Białystok, Poland

Search for other papers by Monika Zbucka-Krętowska in
Google Scholar
PubMed
Close
,
Marcin Adamski Faculty of Computer Science, Bialystok University of Technology, Białystok, Poland

Search for other papers by Marcin Adamski in
Google Scholar
PubMed
Close
, and
Adam Jacek Krętowski Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland
Clinical Research Centre, Medical University of Bialystok, Białystok, Poland

Search for other papers by Adam Jacek Krętowski in
Google Scholar
PubMed
Close

Treatment with radioactive iodine (RAI) in women with differentiated thyroid cancer is associated with decreased serum concentrations of anti-Müllerian hormone (AMH); however, other markers have not been investigated. Therefore, this study aimed to evaluate the effect of RAI treatment on antral follicle count (AFC) and the serum concentration of inhibin B, follicle-stimulating hormone (FSH), and AMH in women with papillary thyroid cancer (PTC) treated with RAI. We examined 25 women at a median age of 33 years treated with a single dose of RAI. We divided the participants into women over (n = 11) and under 35 years of age (n = 14). Serum concentrations of inhibin B, FSH, AMH, and AFC were assessed at baseline and 1 year after RAI treatment. We found decreased AFC (P = 0.03), serum levels of AMH (P < 0.01), inhibin B (P = 0.03), but not FSH (P = 0.23), 1 year after RAI treatment in comparison to baseline in the whole group. When we compared serum levels of AMH in younger vs older women separately, we observed a significant reduction of this hormone’s serum level after RAI treatment in both groups (P < 0.01; P = 0.04, respectively). We concluded that RAI treatment significantly impacts the functional ovarian reserve in premenopausal women with PTC.

Open access
Wolfgang Koechling Ferring Pharmaceuticals A/S, Copenhagen, Denmark

Search for other papers by Wolfgang Koechling in
Google Scholar
PubMed
Close
,
Daniel Plaksin Bio-Technology General Israel Ltd, Ferring Pharmaceuticals, Kiryat Malachi, Israel

Search for other papers by Daniel Plaksin in
Google Scholar
PubMed
Close
,
Glenn E Croston Croston Consulting, San Diego, California, USA

Search for other papers by Glenn E Croston in
Google Scholar
PubMed
Close
,
Janni V Jeppesen The Laboratory of Reproductive Biology, The Department of Fertility at The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and The University of Copenhagen, Copenhagen, Denmark

Search for other papers by Janni V Jeppesen in
Google Scholar
PubMed
Close
,
Kirsten T Macklon The Laboratory of Reproductive Biology, The Department of Fertility at The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and The University of Copenhagen, Copenhagen, Denmark

Search for other papers by Kirsten T Macklon in
Google Scholar
PubMed
Close
, and
Claus Yding Andersen The Laboratory of Reproductive Biology, The Department of Fertility at The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and The University of Copenhagen, Copenhagen, Denmark

Search for other papers by Claus Yding Andersen in
Google Scholar
PubMed
Close

Recombinant FSH proteins are important therapeutic agents for the treatment of infertility, including follitropin alfa expressed in Chinese Hamster Ovary (CHO) cells and, more recently, follitropin delta expressed in the human cell line PER.C6. These recombinant FSH proteins have distinct glycosylation, and have distinct pharmacokinetic and pharmacodynamic profiles in women. Comparative experiments demonstrated that follitropin delta and follitropin alfa displayed the same in vitro potency at the human FSH receptor, but varied in their pharmacokinetics in mouse and rat. While follitropin delta clearance from serum depended in part on the hepatic asialoglycoprotein receptor (ASGPR), follitropin alfa clearance was unaffected by ASGPR inhibition in rat or genetic ablation in mice. The distinct properties of follitropin delta and follitropin alfa are likely to contribute to the differing pharmacokinetic and pharmacodynamic profiles observed in women and to influence their efficacy in therapeutic protocols for the treatment of infertility.

Open access